More than 300 people across academia and industry spilled into an auditorium to attend a BoltzGen seminar on Thursday, Oct. 30, hosted by the Abdul Latif Jameel Clinic for Machine Learning in Health (MIT Jameel Clinic). Headlining the event was MIT PhD student and BoltzGen’s first author Hannes Stärk, who had announced BoltzGen just a few days prior.
Building upon Boltz-2, an open-source biomolecular structure prediction model predicting protein binding affinity that made waves over the summer, BoltzGen (officially released on Sunday, Oct. 26.) is the first model of its kind to go a step further by generating novel protein binders that are ready to enter the drug discovery pipeline.
Three key innovations make this possible: first, BoltzGen’s ability to carry out a variety of tasks, unifying protein design and structure prediction while maintaining state-of-the-art performance. Next,
